Coming December: ASH publishes its late-breaking abstracts. We’ll add the organizations presenting them.

Emory University at ASH 2026

Dec 12–15, 2026 New Orleans, LA ~30k attendees Website

Emory University brings 37 presentations to ASH 2026 in New Orleans. Its program centres on sickle cell disease and blood cancers. It covers a new treatment for acute pain events in a sickle mouse model, vitamin D replacement in adults and mantle cell lymphoma outcomes across treatment eras.

OrganizationASH 2026 Attendance
Emory University
Atlanta, GA
Universities & research institutes
Private research university in Atlanta, Georgia, with a school of medicine.
Symposium
Fri Dec 11
7:00pm–10:00pm
Cases and Conversations: Endothelial Injury, Complement, and TA-TMA After Allogeneic Stem Cell Transplant
Picking graft sources such as expanded cord blood, and treating transplant-associated thrombotic microangiopathy with a newly approved complement inhibitor.
Cell & gene · Clotting
Talk
Sun Dec 13
9:30am–11:00am
Vessel on a Chips, Organoids and Clots: A New Era in Thrombosis Research
Tiny engineered vessels that keep their lining alive for weeks, letting researchers watch a clot form, organize, and dissolve while testing new drugs.
Clotting
Talk
Sun Dec 13
4:30pm–5:45pm
Procurement of Blood for Highly Alloimmunized Patients
What determines how fast antigen-matched blood can be found for patients with many red cell antibodies, and alternatives when none is available.
Red cells
Talk
Mon Dec 14
2:45pm–4:00pm
Complement Inhibition in Sickle Cell Disease
How the complement immune system drives hemolysis, vessel injury, pain crises and organ damage in sickle cell disease, and trials of complement-blocking drugs.
Red cells
Session
Mon Dec 14
2:45pm–4:00pm
Improving Care of Patients with Sickle Cell Disease via Complement, Pain Control, and Trial Design
Sickle cell disease pain, from new insights into its biology to managing it at the level of health systems, strategies, and individual treatments.
Red cells
Talk
Mon Dec 14
4:30pm–5:45pm
The Role of Iron in Myelodysplastic Syndrome Progression
Iron overload in myelodysplastic syndromes, built up by failed red cell production and repeated transfusions, and how it pushes disease toward acute leukemia.
Red cells

Explore the full ASH 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in New Orleans. Leave your work email and we’ll be in touch.

Privacy

Download the full ASH 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Emory University

Tell us what you sell and we’ll find the people at Emory University most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction